EMPIRI, Inc. Selected into the 2025 BioTools Innovator Cohort

We are incredibly honored to be named one of just 31 companies in the prestigious BioTools Innovator 2025 cohort, selected from over 420 applicants worldwide!  This highly competitive program, run by the premier global accelerator for life science tools and diagnostics, recognizes the most innovative early-stage companies poised to transform healthcare. 

At EMPIRI, our E-Slice platform is revolutionizing functional precision diagnostics by enabling real-time, ex vivo testing of intact patient tumors—without dissociation or artificial growth factors. This technology delivers actionable insights for oncology drug development and personalized treatment in just 4-8 days, preserving the native tumor microenvironment for unparalleled accuracy. 

Being chosen from such a competitive pool (less than 20% of applicants even make it to the live pitch stage!) validates the potential of E-Slice to reshape preclinical drug discovery and clinical oncology. We’re excited to engage with BioTools Innovator’s world-class mentors, investors, and industry leaders to accelerate our mission of improving patient outcomes.

A huge thank you to BioTools Innovator for this opportunity and to our team for their relentless dedication. Stay tuned for updates as we leverage this platform to drive EMPIRI’s growth and impact!